Dr. Yao Zhu: Tailoring Prostate Cancer Treatment in China, Fudan University Shanghai Cancer Center’s Team Explores Strategies to Benefit More Patients
Due to factors such as early screening, drug accessibility, and genetic differences, prostate cancer characteristics in China differ from those in Western countries. In recent years, with China's aging population, the incidence and mortality of prostate cancer have risen significantly, increasing the disease burden. At the recent CSCO Annual Meeting, Urology Frontier invited Dr. Yao Zhu from Fudan University Shanghai Cancer Center to share insights on the characteristics of prostate cancer in China, the latest research progress at Fudan, and the value of clinical research by physicians.
CSCO 2024丨Dr. Ou Bai: The Development and Growth of the Lymphoma Specialty at The First Bethune Hospital of Jilin University
From September 25-29, 2024, the "27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting," hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, will be held in Xiamen. The conference, themed "Patient-Centered, Sharing the Future," brings together the latest research advancements and developments in the field, both domestically and internationally. For more than 20 years, CSCO has been at the forefront of clinical oncology in China, with experts deeply involved in its growth, advancing their careers through this platform. Hematology Frontier has launched a special "Growing with CSCO" series, inviting Chinese scholars to revisit past stories. In this issue, we invited Dr. Ou Bai, a member of the CSCO United Committee for Lymphoma Intervention (UCLI) and a key figure in the development of the lymphoma specialty at The First Bethune Hospital of Jilin University, to share the story of growing together with CSCO.
CSCO 2024丨Dr. Sanjun Cai: Perioperative “Three-Pronged Strategy” Brings More Options for Colorectal Cancer Treatment
From September 25 to 29, 2024, the 27th Annual National Clinical Oncology Conference and CSCO Academic Annual Meeting was successfully held in Xiamen. With the theme "Patient-Centered, Sharing the Future," the conference gathered significant research progress and developments from both domestic and international fields. Dr. Sanjun Cai from Fudan University Shanghai Cancer Center chaired the special session on perioperative treatment for colorectal cancer at this year’s conference. During the event, Oncology Frontier conducted an interview with Professor Cai to discuss recent advances and challenges in perioperative colorectal cancer treatment. Below is a summary of the interview to provide insight for the readers.
CSCO 2024 | Dr. Gong Chen Provides an In-Depth Analysis of the Changing Treatment Paradigm for Locally Advanced Colorectal Cancer
From September 25 to 29, 2024, the much-anticipated 27th Annual Chinese Society of Clinical Oncology (CSCO) conference was held successfully in Xiamen. This prominent event gathered top experts from China's oncology community, focusing on standardized pathways and cutting-edge advancements in the diagnosis and treatment of malignant tumors.During the conference, Dr. Gong Chen from the Sun Yat-sen University Cancer Center delivered a well-received presentation titled "The Evolving Treatment Paradigm for Locally Advanced Colorectal Cancer." In this golden moment of academic exchange, Oncology Frontier conducted a deep interview with Professor Chen. The discussion centered around the latest advancements in the treatment of locally advanced colorectal cancer and his long-standing academic connection with CSCO, offering an insightful blend of professional wisdom and personal emotion.
CSCO 2024 | Dr. Baorui Liu: “Rapid Advancements in Gastric Cancer Treatment, A Bright Future for Young Scholars”
The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting was held in Xiamen from September 25 to 29, 2024. This year’s theme, “Patient-Centered, Future-Sharing,” brought together major research advancements and developments from around the world. A dedicated gastric cancer session was organized, gathering top experts in the field to explore the latest progress, technologies, and concepts in gastric cancer treatment. We invited Dr. Baorui Liu, Chair of the gastric cancer session and Director of the Oncology Center at Nanjing Drum Tower Hospital,The Affiliated Hospita of Nanjing University Medical School to share key highlights and discussions from the session.
ETER100 Study Showcased at ESMO Late-Breaking Abstract Session: Dr. Xinan Sheng Shares New Advances in Targeted and Immunotherapy
Renal cell carcinoma (RCC) is one of the most common malignancies of the urinary system. In recent years, the exploration of combined immunotherapy strategies in RCC has transformed the treatment landscape, making immuno-targeted therapy the global first-line standard for advanced renal cancer. The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain, from September 13 to 17. During the Urothelial Cancer (non-prostate) Short Oral Presentation session on September 15, Dr. Xinan Sheng from Peking University Cancer Hospital delivered a presentation titled "Anlotinib in combination with the anti-PD-L1 antibody Benmelstobart (TQB2450) versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC) - A randomized, open-label, phase III study (ETER100)." This was the only late-breaking abstract (LBA) study from China selected in the field of uro-oncology at this year's ESMO conference. Urology Frontier invited Professor Sheng to elaborate on the current state of advanced renal cancer treatment in China, the survival benefits and safety of combined immunotherapy in advanced RCC, and other key topics.
Dr. Hao Zeng Shares the West China Hospital Team’s Experience in Treating Special Types of Renal Cancer and Clinical Exploration
Renal cancer is one of the three major tumors of the urinary system. Several large phase III studies on combined targeted and immunotherapy have been successful, and the 2024 update of the CSCO renal cancer diagnosis and treatment guidelines has officially brought first-line treatment for advanced renal cancer into the era of combined targeted and immunotherapy in China. But what are the remaining unmet needs for patients with special types of renal cancer? During the 31st Urology Academic Conference held in Tianjin, Urology Frontier invited Dr. Hao Zeng from West China Hospital, Sichuan University to share his insights on the evolving treatment concepts for advanced renal cancer, the value of combined targeted and immunotherapy, and the West China Hospital team’s exploration into treating special types of renal cancer.
ESMO 2024丨Dr. Silke Gillessen: Radium-223 Combined with Enzalutamide Offers New Hope for Bone Metastatic mCRPC Patients
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13 to 17 in Barcelona, Spain. Key research in the field of urologic oncology garnered much attention, particularly in the area of prostate cancer. The EORTC-GUCG 1333/PEACE-3 clinical trial (LBA1 - A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3) evaluated the efficacy of Radium-223 (Ra-223) combined with enzalutamide compared to enzalutamide alone in patients with bone metastatic castration-resistant prostate cancer (mCRPC) who were asymptomatic or had mild symptoms. The promising results sparked widespread interest. Urology Frontier invited the lead investigator of the study, Dr. Silke Gillessen from the Medical Oncology of the Università della Svizzera Italiana (USI) and Oncology Institute of Southern Switzerland (IOSI), to share her insights on this important research and discuss the potential treatment outlook for bone metastatic mCRPC patients.